Social Media

Mankind Pharma forays into digital platform

Our Bureau Mumbai | Updated on September 02, 2020 Published on September 02, 2020

The app works like a “virtual clinic” and will help a doctor communicate with regular patients

To promote an app for doctors


Mankind Pharma will market DrOnA, or an app to bring doctors closer to their patients. The move makes Mankind Pharma the latest drug-maker to partner with a company, Appify that has a digital footprint.

It works like a “virtual clinic” and will help a doctor communicate with regular patients, besides getting access to the latest scientific journals etc, explains Chanakya Juneja, part of Mankind Pharma’s promoter family.

The best part of the app is that a person can pay on the app and fix up an appointment for an older member in the family to have a tele-consultation, he told BusinessLine, adding that Mankind Pharma had no other involvement or investment with the app or data being generated by the app. Maintaining that the app was to streamline activities for doctors, he said, a doctor was also free to uninstall the app and take all the data with him or her.


Rajeev Juneja, Mankind Pharma’s Chief Executive Officer and Chanakya’s father, said that facility would also help with repeat consults, after an initial face-to-face consult in a post-Covid world.

The move comes even as the Centre plans for a digital health footprint across the country to streamline doctor-patient interactions, among other things. The digital future is also fuelling mega buyouts in the online sale of medicines, even as concerns are being raised on the sanctity of the patient’s data. Interestingly, healthcare companies like Roche Diabetes Care have digital plans for a doctor platform later this year, while Abbott had announced a “neutral” digital initiative for doctors and consumers, last year.

Preparing for Covid challenges

Meanwhile, the senior Juneja said, the company expected to end the current year with a turnover of about ₹6,400-odd crore (compared to ₹5,900 crore last year). The company is presently undertaking trials for Niclosamide, from South Korean firm Daewoong Pharmaceutical Co Ltd, used in the treatment of Covid-19.

Looking back, he said, the company had understood that something was amiss in February and stocked up on inventory, before the national lockdown. Presently stocks are in place or the entire year, he added.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on September 02, 2020
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.